What are the safety, toxicity and oncologic outcomes of patients undergoing transoral robotic surgery (TORS), neck dissection and adjuvant therapy for advanced oropharyngeal squamous cell carcinoma (AOC)?
Explore this issue:April 2011
Background: Most patients with AOC in the U.S. are treated with definitive chemoradiation therapy. The U.S. Food and Drug Administration recently approved TORS for surgical treatment of AOC.
Study design: Retrospective cohort study of 47 patients with stage III-IV AOC undergoing TORS, all with minimum 18 months of follow-up. Reasons for exclusion included distant metastases, T4a disease (except for deep tongue muscle invasion), T4b disease, trismus or unresectable nodal metastases. The decision for adjuvant therapy was based on pathologic analysis.